Concise review: Immunomodulatory properties of mesenchymal stem cells in cellular transplantation: Update, controversies, and unknowns

Stem Cells Translational Medicine

Volumn 1, Issue 3, 2012, Pages 200-205

  Rony, Atoui ^a   Chiu, Ray C J ^b  

^a SUDBURY REGIONAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Immunogenicity; Immunosuppression; Marrow stromal stem cells; Mesenchymal stem cells; Stem cell transplantation

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; INDOLEAMINE 2, 3 DIOXYGENASE; INTEGRIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

ADULT STEM CELL; B LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; GRAFT VERSUS HOST REACTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MULTICENTER STUDY (TOPIC); NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; ANIMAL; CYTOLOGY; HISTOCOMPATIBILITY; IMMUNOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PHYSIOLOGY;

ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84872107813     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2011-0012     Document Type: Review

References (50)

1. Orlic D, Hill J, Arai A. Stem cells for myocardial regeneration. Circ Res 2002;91:1092-1102.
2. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;401:701-705.
3. Dai W, Hale S, Martin B et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: Short and longterm effects. Circulation 2005;112-214-23.
4. Tang Y, Zhao Q, Qin X et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg 2005;80:229-237.
5. Schächinger V, Erbs S, Elsasser A et al. Intra-coronary bone marrow derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210-1221.
6. Zhuo Y, Li SH, Chen MS et al. Aging impairs the angiogenic response to ischemic injury and the activity of implanted cells: Combined consequences for cell therapy in older recipients. J Thorac Cardiovasc Surg 2010;139:1286-1294.
7. Nayan M, Paul A, Chen G. Superior therapeutic potential of young bone marrow mesenchymal stem cells by direct intramyocardial delivery in aged recipients with acute myocardial infarction: In vitro and in vivo investigation. J Tissue Eng 2011;2011:741213.
8. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007;110:3499-3506.
9. Pittenger MF, MacKay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
10. Le Blanc K, Tammik C, Rosendahl K et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31:890-896.
11. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007;262:509-525.
12. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T lymphocyte proliferation induced by cellular or non-specific mitogenic stimuli. Blood 2002;99: 3838-3843.
13. Atoui R, Shum-Tim D, Chiu RCJ. Myocardial regenerative therapy: Immunologic basis for the potential "universal donor cells." Ann Thorac Surg 2008;86:327-334.
14. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res 2006; 312:2169-2179.
15. Bartholomew A, Sturgeon C, Satskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30: 42-48.
16. Tse WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implication in transplantation. Transplantation 2003;75: 389-397.
17. Aggarwal S, Pittenger M. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-1822.
18. Zhang W, Ge W, Li C et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cell Dev 2004;13: 263-271.
19. Beyth S, Borovsky Z, Mevorach D et al. Human mesenchymal stem cells alter antigenpresenting cell maturation and induce T cell unresponsiveness. Blood 2005;105:2214-2219.
20. Maccario R, Podesta M, Moretta A et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4 T-cell subsets expressing a regulatory/ suppressive phenotype. Haematologica 2005; 90:516-525.
21. Djouad F, Plence P, Bony C et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102:3837-3844.
22. Rasmusson I, Ringden O, Sundberg B et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76:1208-1213.
23. Glennie S, Soeiro I, Dyson PJ et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005;105:2821-2827.
24. Kassis I, Vaknin-Dembinsky A, Karussis D. Bone marrow mesenchymal stem cells: Agents of immunomodulation and neuroprotection. Curr Stem Cell Res Ther 2011;6:63-68.
25. Spaggiari GM, Capobianco A, Becchetti S et al. Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2 induced NK-cell proliferation. Blood 2006;107:1484-1490.
26. Koç ON, Day J, Nieder M et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy and Hurler syndrome. Bone Marrow Transplant 2002;30: 215-222.
27. Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002;99:8932-8937.
28. Zappia E, Casazza S, Pedemonte E et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106:1755-1761.
29. Le Blanc K, Rasmusson J, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.
30. Caparelli DJ, Cattaneo SM, Shake JG et al. Cellular cardiomyoplasty with allogeneic mesenchymal stem cells results in improved cardiac performance in a swine model of myocardial infarction. Circulation 2001;104:II-599.
31. Makkar RR, Price M, Lill M et al. Intramyocardial injection of allogeneic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model of myocardial infarction. J Cardiovasc Pharmacol Ther 2005;10: 225-233.
32. Amado LC, Saliaris AP, Schuleri KH et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A, 2005;102:11474-11479.
33. Chiu R. "Stealth immune tolerance in stem cell transplantation: Potential for "universal donors" in myocardial regenerative therapy. J Heart Lung Transplant 2005;24:511-516.
34. Liechty KW, MacKenzie TC, Shaaban AF et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000;6:1282-1286.
35. Saito T, Kuang JQ, Bittira B et al. Xenotransplant cardiac chimera: Immune tolerance of adult stem cells. Ann Thorac Surg 2002;74: 19-24.
36. MacDonald D, Saito T, Shum-Tim D et al. Persistence of marrow stromal cells implanted into acutely infarcted myocardium: Observations in a xenotransplant model. J Thorac Cardiovasc Surg 2005;130:1114-1121.
37. Luo J, Shum-Tim D, Chiu RCJ. Marrow stromal cells as universal donor cells for cardiac regenerative therapy: Fact or fancy? In: Dimarakis I et al., eds. Stem Cell Therapy in Ischemic Heart Disease. London, Imperial College Press, 2009:117-137.
38. Atoui R, Asenjo JF, Duong M et al. Marrow stromal cells as "universal donor cells" for myocardial regenerative therapy: Their unique immune tolerance. Ann Thorac Surg 2008;85: 571-580.
39. Grinnemo K, Mansson A, Dellgren D et al. Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg 2004;127:1293-1300.
40. Grinnemo KH, Mansson-Broberg A, Leblanc K et al. Human mesenchymal stem cells do not differentiate into cardiomyocytes in a cardiac ischemic xenomodel. Ann Med 2006;38: 144-153.
41. Stolzing A, Scutt A. Age-related impairment of mesenchymal progenitor cell function. Aging Cell 2006;5:213-224.
42. Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: Paradoxes of passaging. Exp Hematol 2004;32:414-425.
43. Eliopoulos N, Stagg J, Lejeune L et al. Allogeneic marrow stromal cells are immune rejected by MHC class I-and class II-mismatched recipient mice. Blood 2005;106:4057-4065.
44. Nauta AJ, Westerhuis G, Kruisselbrink AB et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006;108:2114-2120.
45. Stagg J, Pommey S, Eliopoulos N et al. Interferon-÷-stimuated marrow stromal cells: A new type of nonhematopoietuc antigen-presenting cell. Blood 2006;107:2570-2577.
46. Teng CJ, Luo J, Chiu RC et al. Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: Implications for cellular cardiomyoplasty. J Thorac Cardiovasc Surg 2006;132:628-632.
47. Prasad VK, Lucas KG, Kleiner GI et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011; 17:534-541.
48. Matzinger P. The danger model: A renewed sense of self. Science 2002;296:301-305.
49. Zambrano J, Traverse J, Henry T et al. The impact of intravenous human mesenchymal stem cells (Provacel) on ejection fraction in patients with myocardial infarction. Circulation 2007;116:II-202.
50. Kinkaid HY, Huang XP, Li RK et al. What's new in cardiac cell therapy? Allogeneic bone marrow stromal cells as "universal donor cells." J Card Surg 2010;25:359-366.